KADIAN by AbbVie is clinical pharmacology morphine is a natural product that is the prototype for the class of natural and synthetic opioid analgesics. Approved for moderate to severe pain, around-the-clock opioid analgesic is needed for an extended period of time (see ). First approved in 1996.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
KADIAN is an extended-release oral capsule formulation of morphine sulfate, a pure opioid agonist used to treat moderate to severe pain requiring around-the-clock opioid therapy for extended periods. It works by binding to opioid receptors throughout the central and peripheral nervous system to produce analgesia and sedation. The polymer-coated pellet technology delivers morphine more slowly than conventional formulations, achieving lower peak concentrations and higher trough levels at steady state.
Product approaching loss of exclusivity with declining competitive pressure (30%), signaling smaller brand team and transition planning focus.
CLINICAL PHARMACOLOGY Morphine is a natural product that is the prototype for the class of natural and synthetic opioid analgesics. Opioids produce a wide spectrum of pharmacologic effects including analgesia, dysphoria, euphoria, somnolence, respiratory depression, diminished gastrointestinal…
Worked on KADIAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
KADIAN presents limited growth career trajectory as a LOE-approaching product with minimal linked job openings and declining competitive pressure. Professionals joining this team should expect legacy brand management, pricing defense, and potential transition planning rather than expansive market development.